https://doi.org/10.4081/qrmh.2017.7006
0
0
0
0
Smart Citations0
0
0
0
Citing PublicationsSupportingMentioningContrasting
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
If my cholesterol is…then I foresee…: patient accounts of uncertainty
CDC Centers for Disease Control and Prevention. Deaths and mortality. Retrieved 9-28-
Available from https://www.cdc.gov/nchs/fastats/deaths.htm
Birtcher K. When compliance is an issue—how to enhance statin adherence and address adverse effects. Curr Atheroscler Rep 2015; 17: 471-478.
DOI: https://doi.org/10.1007/s11883-014-0471-8
CDC Centers for Disease Control and Prevention. Cholesterol. c2015 [cited 2017 Aug 9]. Available from http://www.cdc.gov./cholesterol/facts.htm
Aggarwal B, Mosca L. Lifestyle and psychosocial risk factors predict non-adherence to medication. Ann Behav Med 2010; 40: 228-233.
DOI: https://doi.org/10.1007/s12160-010-9212-6
American Heart Association. Heart disease and stroke statistics: Our guide to current statistics and the supplement to our Heart and Stroke Facts. Dallas, TX: AHA; 2008.
Ho CKM, Walker SW. Statins and their interactions with other lipid-modifying medications: Safety issues in the elderly. Ther Adv Drug Safety 2012; 3: 35-46.
DOI: https://doi.org/10.1177/2042098611428486
Christensen AJ. Patient adherence to medical treatment regimens: Bridging the gap between behavioral science and biomedicine. New Haven, CT: Yale University Press; 2004.
Cook PF. Adherence to medications. In: W. T. O’Donohue WT, Levensky ER, eds. Promoting treatment adherence: A practical handbook for health care providers. Thousand Oaks, CA: Sage; 2006. pp. 183-202.
DOI: https://doi.org/10.4135/9781452225975.n12
Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007; 21: 311-316.
DOI: https://doi.org/10.1007/s10557-007-6040-4
Mann DM, Ponieman D, Montori VM, Arciniega J, McGinn T. The statin choice decision aid in primary care: A randomized trial. Patient Educ Couns 2010; 80:138-140.
DOI: https://doi.org/10.1016/j.pec.2009.10.008
Abbass I, Revere L, Mitchell J, Appari A. Medication nonadherence: the role of cost, community, and individual factors. Health Services Res 2017; 52: 1511-1533.
DOI: https://doi.org/10.1111/1475-6773.12547
Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient education. J Clin Lipidol 2013; 7: 472-483.
DOI: https://doi.org/10.1016/j.jacl.2013.03.001
Sirtori CR. The pharmacology of statins. Pharmacol Res 2014; 88: 3-11.
DOI: https://doi.org/10.1016/j.phrs.2014.03.002
Macedo AF, Taylor FC, Casas, JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014; 12: 1-13.
DOI: https://doi.org/10.1186/1741-7015-12-51
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010; 375: 735-742.
DOI: https://doi.org/10.1016/S0140-6736(09)61965-6
Jukema JW, Cannon CP, de Craen AJM, Westendorp RGJ, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 2012; 60:875-881.
DOI: https://doi.org/10.1016/j.jacc.2012.07.007
Cholesterol Treatment Trialists’ (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590.
DOI: https://doi.org/10.1016/S0140-6736(12)60367-5
Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol 2010; 4: 462-471.
DOI: https://doi.org/10.1016/j.jacl.2010.08.026
O’Neil A, Sanna L, Redlich C, et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med 2012; 10: 1-9.
DOI: https://doi.org/10.1186/1741-7015-10-154
Swiger KJ, Manalac RJ, Blaha, MJ, Blumenthal RS, Martin SS. Statins, mood, sleep, and physical function: a systematic review. Eur J Clin Pharmacol 2014; 70: 1413-1422.
DOI: https://doi.org/10.1007/s00228-014-1758-y
Chakraborty S. Part I: The role of trust in patient noncompliance: A qualitative case study of users of statins for the chronic treatment of high-cholesterol in New York City. J Risk Res 2013; 16: 97-112.
DOI: https://doi.org/10.1080/13669877.2012.727097
Babrow AS. Problematic integration theory. In: Whaley B, Samter W, eds. Explaining communication: Contemporary theories and exemplars. Mahwah, NJ: Lawrence Erlbaum Associates; 2007. pp. 181-200.
Babrow AS. Communication and problematic integration: Understanding diverging probability and value, ambiguity, ambivalence, and impossibility. Commun Theory 1992; 2: 95-130.
DOI: https://doi.org/10.1111/j.1468-2885.1992.tb00031.x
Babrow AS. Uncertainty, value, communication, and problem integration. J Commun 2001; 51: 553-573.
DOI: https://doi.org/10.1111/j.1460-2466.2001.tb02896.x
Babrow AS, Hines SC, Kasch CR. Managing uncertainty in illness explanation: An application of problematic integration theory. In: Whaley B, ed. Explaining illness: Research, theory, and strategies. Mahwah, NJ: Lawrence Erlbaum Associates; 2000. pp. 41-67.
Keller V F, Drummond DK, Bueno Y, Spadola J, Schy E. Final report: Understanding statin non-adherence: A qualitative study. Prepared for the Innovation Center, AstraZeneca. UM-Humana Health Services Research Center; May, 2007.
McCracken G. The long interview. Newbury Park, CA: Sage; 1988.
DOI: https://doi.org/10.4135/9781412986229
Owen WF. Interpretive themes in relational communication. Q J Speech 1984; 70: 274-287.
DOI: https://doi.org/10.1080/00335638409383697
Doherty WJ, Campbell TL. Families and health. Thousand Oaks, CA: Sage; 1988.
Sells D, Sledge WH, Wieland M, et al. Cascading crises, resilience and social support within the onset and development of multiple chronic conditions. Chronic Illn 2009; 5: 92-102.
DOI: https://doi.org/10.1177/1742395309104166
Kirkegaard P, Edwards A, Risor MB, Thomsen JL. Risk of cardiovascular disease? A qualitative study of risk interpretation among patients with high cholesterol. BMC Fam Pract 2013; 14: 137-142.
DOI: https://doi.org/10.1186/1471-2296-14-137
Russell LD, Babrow AS. Risk in the making: Narrative, problematic integration, and the social construction of risk. Commun Theory 2011; 21: 239-260.
DOI: https://doi.org/10.1111/j.1468-2885.2011.01386.x
Niederdeppe J, Byrne S, Avery RJ, Cantor J. Direct-to-consumer television advertising exposure, diagnosis with high-cholesterol, and statin use. J Gen Intern Med 2013; 28: 886-893.
DOI: https://doi.org/10.1007/s11606-013-2379-3
Byrne S, Niederdeppe J, Avery RJ, Cantor J. “When diet and exercise are not enough”: An examination of lifestyle change inefficacy claims in direct-to-consumer advertising. Health Commun 2013; 28: 800-813.
DOI: https://doi.org/10.1080/10410236.2012.725125
How to Cite
Drummond, Darlene K. 2017. “If My Cholesterol is…then I foresee…: Patient Accounts of Uncertainty”. Qualitative Research in Medicine and Healthcare 1 (3). https://doi.org/10.4081/qrmh.2017.7006.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
